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Molecular imaging receives increased attention for selecting
patients who will benefit from targeted anticancer therapies. Neo-
ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment
Optimisation) enrolled 455 women with invasive human epidermal
growth factor receptor 2 (HER2)–positive breast cancer and com-
pared rates of pathologic complete response (pCR) to neoadjuvant
lapatinib, trastuzumab, and their combination. Each anti-HER2 ther-
apy was given alone for 6 wk, followed by 12 wk of the same
therapy plus weekly paclitaxel. The early metabolic effects of the
anti-HER2 therapies on the primary tumors and their predictive val-
ues for pCR were assessed in a subset of patients. Methods:
Eighty-six patients underwent 18F-FDG PET/CT at baseline and
weeks 2 and 6 of anti-HER2 treatment. An imaging core laboratory
provided central validation, and 2 independent reviewers, masked
to assigned treatment arm and clinical outcomes, performed con-
sensus 18F-FDG PET/CT readings. Maximum standardized uptake
value (SUVmax) reductions from baseline were used to measure
metabolic response. Results: Seventy-seven of the 86 enrolled
patients presented an evaluable baseline 18F-FDG PET/CT scan;
of these, 68 and 66 were evaluable at weeks 2 and 6, respectively.
Metabolic responses in the primary tumors were evident after 2 wk
of targeted therapy and correlated highly with metabolic responses
at week 6 (R2 5 0.81). pCRs were associated with greater SUVmax
reductions at both time points. Mean SUVmax reductions for pCR
and non-pCR, respectively, were 54.3% versus 32.8% at week 2
(P 5 0.02) and 61.5% versus 34.1% at week 6 (P 5 0.02). 18F-FDG
PET/CT metabolic response rates at weeks 2 and 6 were 71.6%
and 60%, respectively using European Organization for Research
and Treatment of Cancer criteria; pCR rates were twice as high for
18F-FDG PET/CT responders than nonresponders (week 2: 42%
vs. 21%, P 5 0.12; week 6: 44% vs. 19%, P 5 0.05). Conclusion:
Early metabolic assessment using 18F-FDG PET/CT can identify
patients with an increased likelihood of pCR after neoadjuvant
trastuzumab, lapatinib, or their combination when given with
chemotherapy.
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Approximately 20% of all breast cancers (BCs) overexpress or
amplify the human epidermal growth factor receptor 2 (HER2),
a characteristic associated with poor prognosis, increased prolif-
eration, angiogenesis, and resistance to apoptosis (1–3).
In combination with chemotherapy, the monoclonal antibody
trastuzumab (Herceptin; Genentech), which specifically targets the
HER2 extracellular domain, has been shown to improve survival
in both the adjuvant and the metastatic settings (4–8). In addition,
lapatinib (Tykerb; GlaxoSmithKline), a small-molecule inhibitor
that targets the intracellular domain of HER2, has established its
benefit in treating HER2-positive metastatic BC when combined
with capecitabine or letrozole (9,10).
Preclinical and clinical studies showing that lapatinib resensi-
tizes tumors that have progressed on trastuzumab (11–13) provided
the first indication that combining the agents to create a dual anti-
HER2 blockade may improve the current standard of care even
further. Lapatinib and trastuzumab do have partly nonoverlapping
mechanisms of action: trastuzumab inhibits ligand-independent
HER2 and HER3 signaling (14) and triggers antibody-dependent
cellular cytotoxicity (15). By contrast, lapatinib blocks ligand-
induced heterodimer signaling and prevents signaling via a fre-
quently expressed truncated version of HER2 that could render
cells resistant to trastuzumab. Additionally, lapatinib leads to an
accumulation of HER2 at the cell surface, enhancing trastuzumab-
dependent antibody-dependent cellular cytotoxicity (12).
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In the neoadjuvant setting, trastuzumab combined with chemo-
therapy has been shown to significantly increase pathologic
complete response (pCR) (16). According to recent data, higher
pCR rates are in turn associated with improved outcomes (17).
We previously reported that treatment with the lapatinib and
trastuzumab combination in Neoadjuvant Lapatinib and/or Tras-
tuzumab Treatment Optimisation (Neo-ALTTO) resulted in a sig-
nificantly higher pCR rate (51.3%) than with either trastuzumab
(29.5%) or lapatinib (24.7%) alone. Neo-ALTTO randomized 455
patients from 86 sites in 23 countries to receive either lapatinib
alone (n 5 154), trastuzumab alone (n 5 149), or both drugs (n 5
152) for 6 wk, followed by the same assigned targeted therapy
combined with weekly paclitaxel for 12 wk (18).
One of the trial’s key features was the initial 6-wk biologic win-
dow, during which patients received only anti-HER2 drugs. This
protocol enabled us to investigate the effect of anti-HER2 therapy
alone and search for potential molecular and imaging biomarkers of
response. Central to this were 3 serial PET/CT scans with 18F-FDG
performed in a subset of patients at baseline, week 2, and week 6.
A preplanned secondary objective of Neo-ALTTO was to assess
both the early metabolic effects of anti-HER2 blockade on the
primary tumors and their predictive value for pCR at the time of
surgery. There was also interest in exploring whether 18F-FDG
PET imaging would capture a higher rate of metabolic response
with the dual HER2 blockade as opposed to single blockade. Neo-
ALTTO thus represents the first investigation, to our knowledge,
of 18F-FDG PET/CT in patients treated with anti-HER2 therapies
in the neoadjuvant setting.
MATERIALS AND METHODS
Study Design
Patients were randomized to 1 of 3 treatment arms: oral lapatinib,
intravenous trastuzumab, or their combination administered for 6 wk,
followed by 12wkof the assigned anti-HER2 therapy plusweekly paclitaxel
(Fig. 1). Within 4 wk of the last administration of paclitaxel, patients un-
derwent definitive breast surgery and were evaluated for pCR, defined as the
absence of invasive cancer in the breast (19). The ethics committee and
relevant health authorities at each participating institution approved the
study protocol (clinical trial registration number NCT00553358). All
women gave written informed consent before study entry.
Evaluation of HER2/Hormone Receptor (HR) Disease
HER2/HR disease is described in the original manuscript of the
Neo-ALTTO (18): in brief, HER2 and HR status were determined
according to local pathology department criteria. HER2 status was
assessed locally at participating institutions that had been accredited
by the certified laboratory, Vall d’Hebron Institute of Oncology, Bar-
celona.
Selection of 18F-FDG PET/CT Study Sites
A feasibility questionnaire was sent to all sites before patient enroll-
ment to assess their 18F-FDG PET/CT capabilities. Thirty centers in 14
countries were ultimately selected. In these centers, the imaging substudy
was proposed to all consecutive patients included in the Neo-ALTTO trial.
18F-FDG PET/CT Procedures
Three 18F-FDG PET/CT scans were obtained for each patient: 1
before initiation of neoadjuvant treatment (baseline) and 2 more dur-
ing treatment (weeks 2 and 6). All patients were studied using a ded-
icated 18F-FDG PET/CT camera of the brand locally available (GE
Healthcare, Philips, or Siemens). All 18F-FDG PET/CT images had to
be taken using the same scanner and identical acquisition parameters.
Patients were required to have fasted for at least 6 h before the scan
and to have blood glucose levels less than 150 mg/dL before 18F-FDG
injection. The injected activity was 3.7–7.4 MBq/kg, with the differ-
ence of net injected activity between the baseline and the 2 subsequent
scans not to exceed 20%. For all scans, the delay between 18F-FDG
injection and start of image acquisition had to be at least 50 min. For
scans at weeks 2 and 6, the time interval between tracer injection and
start of the PET/CT acquisition needed to fall within 20 min of the
interval recorded for the baseline 18F-FDG PET/CT scan. Any 18F-
FDG PET/CT scan showing a significant paravenous tracer injection
defined as more than 10% of the injected dose was excluded from the
analysis. In all 18F-FDG PET/CT centers, the same iterative recon-
struction method was used for the 3 time points, such as ordered-
subset expectation maximization or row-action maximum likelihood
algorithm, with and without CT-based attenuation correction.
Two nuclear medicine reviewers (in Barcelona and Brussels) retro-
spectively assessed the quality of the 18F-FDG PET/CT scans and im-
aging analysis. They verified and cross-checked the dedicated PET/CT
imaging case report form and the DICOM (Digital Imaging and Com-
munications in Medicine) headers. Face-to-face meetings were held by
the 2 PET/CT reviewers to reach a consensus on assessments.
Selection of Target Tumor Lesions
Lesions were divided according to their location: breast, nodal
(axillary, subclavicular, and internal mammary), and distant.
At baseline, 18F-FDG PET/CT target lesions were defined as those
with a maximum standardized uptake value (SUVmax) $ 2.5 and
a CT based maximal transaxial diameter$ 1 cm. Lesions not fulfilling
these 2 criteria were classified as nontarget. Only target lesions were
included in the statistical analysis.
Assessment of Metabolic Response
SUVmax was obtained by drawing a volume of interest in the
lesions using the commercial PET VCAR software on an Advantage
Workstation (GE Healthcare), which allows a practical approach to
comparative analysis (20).
Lesion-Based Metabolic Response Assessment. SUV is a widely
used 18F-FDG PET/CT quantifier, calculated as the ratio of the con-
centration of the measured tissue radioactivity and the injected radio-
activity normalized for patient body weight. SUVmax represents the
highest pixel SUV within a tumor and is a continuous variable. For
FIGURE 1. Neo-ALTTO study design. B 5 baseline; FEC 5 fluoroura-
cil, epirubicin, cyclophosphamide; w2 5 week 2; w6 5 week 6.
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each target lesion, metabolic response was calculated as the percent-
age decrease of the baseline value according to the following formula:
(SUV baseline – SUV response)/SUV baseline. PET responses were
classified according to criteria of the European Organization for Re-
search and Treatment of Cancer (EORTC) (21).
For the 18F-FDG PET/CT scan performed at week 2, the selected
threshold was 15%, meaning that target lesions showing at least a 15%
reduction of the SUVmax were considered responding. For the 18F-
FDG PET/CT for week 6, the selected threshold was 25%, meaning
that target lesions showing at least a 25% reduction of the SUVmax
were considered responding. For both time points, lesions showing an
increased activity of 25% were classified as progressive lesions. Fi-
nally, also for both time points, if a lesion’s metabolic activity became
visually identical to the local background activity, the response was
classified as a complete metabolic response.
For this analysis, patients whose lesions showed either partial or com-
plete metabolic responses were classified as responders, whereas met-
abolically stable or progressive cases were considered nonresponders.
Region- and Patient-Based Metabolic Response Assessment. The
least responding target lesion was used to categorize region- and
patient-based response. Responses were assessed separately for the
primary breast tumor, lymph nodes, and distant lesions. We also
distinguished primary tumor response from overall response, the latter
including the primary tumor and the nodes. Of note, the few distant
lesions identified were considered as nodal lesions in the analysis.
Statistical Analysis
We hypothesized that with roughly 30 patients per arm undergoing
an early 18F-FDG PET/CT evaluation and by correlating early meta-
bolic changes with pCR at surgery, we would be able to differentiate
patients with HER2-addicted tumors from those with tumors less de-
pendent on HER2 signaling. Because the optimal timing of 18F-FDG
PET/CT in this context was unknown, we decided to perform 18F-FDG
PET/CT imaging at weeks 2 and 6. No formal statistical hypothesis
was planned for this first exploratory analysis.
Metabolic response was first described as the change in SUVmax
from baseline to weeks 2 and 6. The correlation between these changes
was assessed, and the changes in SUVmax were then summarized by
means and box plots.
Although most of the analyses of metabolic response based on
EORTC criteria were descriptive, logistic regression models were




According to the predefined eligibility criteria, 77 of the 86
patients enrolled in Neo-ALTTO presented an evaluable baseline
18F-FDG PET/CT scan and were included; 68 and 66 of those
patients had an evaluable 18F-FDG PET/CT scan at week 2 and
week 6, respectively. Ultimately, 62 patients were fully evaluable
for all 3 time points (Fig. 2).
The main reason for exclusion was failure to comply with tim-
ing for one or more of the 3 assessments (n 5 12). Other reasons
included 18F-FDG PET/CT not performed or lost (n 5 9), insuf-
ficient image quality (n 5 2), and scans obtained with different
18F-FDG PET/CT cameras (n 5 1).
Among the 77 evaluable patients, 52 (67.5%) presented metabolic
lymph node involvement, and 9 (11.7%) presented both metabolic
lymph node involvement and clinically unsuspected distant lesions.
Table 1 shows that the 18F-FDG PET/CT cohort (77 patients) is re-
presentative of the overall Neo-ALTTO population (455 patients), ex-
cept for tumor size, which was found to be slightly larger in the imaging
subgroup (54.5%) than in the general study population (39.8%).
Biologic Window
Correlation Between Week-2 and Week-6 18F-FDG PET/CT
Results. A significant correlation (R2 5 0.81) was found between
the changes of primary tumor SUVmax at weeks 2 and 6 (Fig. 3).
Metabolic Response Rates at Weeks 2 and 6 According to
EORTC Criteria. 18F-FDG PET/CT metabolic response rates in
the primary tumor were 71.6% at week 2 and 60% at week 6.
Similar results were found for overall response (primary tumor
and nodes), with rates of 69% and 56%, respectively.
Absence of response in the primary tumor at week 2 was pre-
dictive of nonresponse at week 6, with a negative predictive value
of 90% (18/20 patients). The presence of response at week 2 was
predictive of response at week 6, with a positive predictive value
of 78.5% (33/42 patients). Figure 4 illustrates 2 examples.
Analysis of metabolic responses in the primary tumor according
to treatment arm revealed the following: at week 2, responses were
66.7%, 56.5%, and 95% for the lapatinib, trastuzumab, and com-
bination arms, respectively (P 5 0.016); at week 6, responses
were 60.9%, 43.5%, and 78.9%, respectively (P 5 0.065). Com-
parison of the metabolic responses for single- versus dual-treatment
arms showed 61.7% and 95% at week 2 (P5 0.013) and 52.2% and
78.9% at week 6 (P 5 0.08), respectively.
Metabolic response rates were higher in patients with HR-
negative tumors than in patients with HR-positive tumors: 82.1%
versus 64.1% at week 2 (P 5 0.18) and 78.5% versus 45.9% at
week 6 (P 5 0.016), respectively.
Of note, 5 (7%) patients (all with HR-negative tumors) showed
complete metabolic response in their primary tumors at week 2, and
14 (21%) patients did so (10 with HR-negative tumors) at week 6.
Correlation Between Metabolic Response and pCR
Of the 77 patients included in this analysis, 27 (35.1%) achieved
pCR at surgery.
Relative Changes in SUVmax in Primary Tumor at Weeks 2 and
6 According to pCR. Patients with pCR at surgery had significantly
greater reductions in SUVmax at weeks 2 and 6 (P5 0.02 for both
time points) than those without a pCR. Mean SUVmax reductions
were 54.3% versus 32.8% at week 2 and 61.5% versus 34.1% at
week 6 for pCR and non-pCR, respectively. Box plots of the
changes in SUVmax are shown in Figure 5.
FIGURE 2. Patients included in 18F-FDG PET/CT analysis.
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pCR by Metabolic Response in Primary Tumor and Overall
Response Using EORTC Criteria. Higher rates of pCR were observed
in responders than nonresponders, independently of the selection
of the target lesion: primary tumor (week 2: 41.6% vs. 21.1%, P5
0.12; week 6: 43.6% vs. 19.2%, P 5 0.05, respectively) with or
without node involvement (Table 2). However, when adjustments
were made for stratification factors and treatment arm in multi-
variate logistic regression models, the odds ratio for metabolic re-
sponse was reduced and no longer statistically significant (P 5
0.19 and 0.24 at weeks 2 and 6, respectively). This appeared pre-
dominantly to be due to the adjustment for HR status, which was
the strongest predictor of pCR.
pCR by Metabolic Response in Primary Tumor According to HR
Status Using EORTC Criteria. HR-positive tumors had a lower
rate of pCR than HR-negative ones: 8 of 43 (18.6%) versus 19 of
34 (55.9%). In addition, HR-positive tumors with metabolic
responses classified as nonresponders had much lower pCR rates
than those classified as responders (1/20 [5%] vs. 4/17 [23.5%] at
week 6). This was not the case for HR-negative tumors: the pCR
rates were comparable for the responders and the nonresponders,
both for the primary tumor and for overall (13/22 [59.1%] vs. 4/6
[66.7%] at week 6) (Table 3).
Complete Metabolic Responses and pCR. Of the patients with
HER2-positive/HR-negative BC, 10 showed a complete metabolic
response at week 6; of these, 9 presented a pCR at the time of surgery.
Of the patients with HER2-positive/HR-positive BC, only 4 showed
complete metabolic response, of which 1 presented a pCR at surgery.
DISCUSSION
Although trastuzumab’s use both in advanced and in early disease
is associated with improved clinical outcomes, so far not a single
FIGURE 3. Correlation between relative changes in SUVmax at week 2
and week 6.
TABLE 1
Patient Characteristics According to Stratification Factors in 18F-FDG PET/CT Population and in
General Neo-ALTTO Population
18F-FDG PET/CT patients Neo-ALTTO patients
Characteristic n % n %
pCR
Yes 27 35.1 160 35.2
No 50 64.9 295 64.8
Locoregional pCR
Yes 27 35.1 138 30.3
No 48 62.3 302 66.4
Missing 2 2.6 15 3.3
Treatment arm
L 26 33.8 154 33.8
T 26 33.8 149 32.7
L 1 T 25 32.5 152 33.4
Lymph node status
N0–1 66 85.7 383 84.2
N21 11 14.3 72 15.8
HR status
Positive 43 55.8 232 51.0
Negative 34 44.2 223 49.0
Breast conservation
Candidate for conservation therapy 22 28.6 130 28.6
Not a candidate for conservation therapy 55 71.4 325 71.4
Breast tumor size (cm)
#5 35 45.5 274 60.2
.5 42 54.5 181 39.8
pCR 5 pathologic complete response (breast); locoregional pCR 5 pathologic complete response (breast 1 lymph nodes); N 5 lymph
node status; L 5 lapatinib arm; T 5 trastuzumab arm; L 1 T 5 lapatinib 1 trastuzumab arm.
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biomarker beyond HER2 has been validated to help us identify the
women most likely to benefit from it. More recent research into anti-
HER2 therapies indicates that using 2 anti-HER2 agents to create
a dual blockade offers further significant clinical advantages (22,23),
but here also biomarker research has been unsuccessful (24).
Although PET/CT imaging has been established as a useful
staging and prognostic instrument, the interest in functional imaging
as a tool to predict pCR to neoadjuvant therapy emerged only a few
years ago (25–29), with promising results shown particularly in tri-
ple-negative BC (30). Neo-ALTTO is the first trial to test whether
early 18F-FDG PET/CT–based metabolic response assessment could
be a clinically useful pharmacodynamic biomarker to select patients
with a high versus low probability of response to a HER2-based
therapy combined with chemotherapy. Be-
cause of Neo-ALTTO’s 6-wk biologic win-
dow of anti-HER2 treatment alone, we could
use 18F-FDG PET/CT to assess the effect of
anti-HER2 treatments without the interfer-
ence of chemotherapy.
Our primary observation was the rapidity
with which metabolic changes occurred in
the tumors after exposure to the anti-HER2
blockade. Metabolic responses were seen at
2 wk in more than two thirds (71.6%) of the
patients, including 5 with a complete meta-
bolic shut-down. Metabolic responses (21)
were more frequent in the dual HER2 block-
ade arm (95% at week 2) than in the single-
agent arms (66.7% for lapatinib, 56.5% for
trastuzumab at week 2), which is consistent
with Neo-ALTTO’s overall results for 455
patients: twice the pCR rate was observed
with trastuzumab plus lapatinib than with
either agent used alone (18). Lapatinib and
trastuzumab do have different mechanisms
of action, possibly explaining the synergy
of metabolic response seen in the combina-
tion arm.
Moreover, the correlation between SUVmax changes at 2 and 6
wk is encouraging. These data clearly show that most of the
decreased 18F-FDG uptake is seen early during treatment. This is
vital both to individualize treatment and to optimize future drug
development.
Equally encouraging is the correlation between early metabolic
response and the likelihood of achieving pCR, the main objective
of the 18F-FDG PET/CT analysis (19). The pCR rate was twice as
high in patients showing an 18F-FDG PET/CT response than it was
in nonresponders. However, 18F-FDG PET/CT nonresponders still
showed a 20% pCR rate, which is clinically meaningful and may
reflect the salvage activity of paclitaxel in some tumors that are
not HER2-addicted. Interestingly, 20% is in line with the pCR rate
FIGURE 4. Representative examples of metabolic responder and nonresponder included in our
study. (A) Metabolic responder achieving pCR: baseline axial fused PET/CT slice showing right
breast tumor (left), week 2 PET/CT metabolic complete response (middle), and week 6 PET/CT
metabolic complete response (right). (B) Metabolic nonresponder not achieving pCR: baseline axial
fused PET/PT slice showing left breast tumor (left), week 2 PET/CT metabolic stable disease (mid-
dle), and week 6 PET/CT metabolic stable disease (right).
FIGURE 5. Box plots of changes in SUVmax: relative SUV max changes and pCR at week 2 (A) and week 6 (B).
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of 22% observed in patients with HER2-positive tumors receiving
only chemotherapy in the neoadjuvant setting (31).
Excellent concordance was also found between imaging results
of the primary tumor alone and those of the primary tumor plus its
adjacent lymph nodes, suggesting that further imaging studies of
early response to preoperative anti-HER2 therapies may be based
solely on primary tumor evaluation.
An unexpected observation was the marked heterogeneity of the
18F-FDG PET/CT response according to HR status. This un-
planned analysis was conducted because of the growing evidence
that HER2-positive/HR-positive disease is different from HER2-
positive/HR-negative disease, with the former showing less dra-
matic responses to chemotherapy plus anti-HER2 therapy.
In our study, 18F-FDG PET/CT responses to HER2-therapy oc-
curred less frequently in HR-positive tumors. This pattern also
extended to metabolic complete responses, which were observed
in only 4 HR-positive tumors but in 10 HR-negative tumors, and
correlated less well to the achievement of pCR (1/4 pCRs for HR-
positive tumors contrasting with 9/10 pCRs for HR-negative ones).
Surprisingly, 18F-FDG PET/CT response turned out to be a weaker
predictor of pCR than HR status, with HR-negative tumors being
more likely than HR-positive ones to reach a pCR. Also notable is
the apparent greater salvage effect of chemotherapy in patients with
HR-negative BC classified as nonresponders than in nonresponders
with HR-positive BC. This may explain the much better negative
predictive value of the early 18F-FDG PET/CT in the latter group.
The potential weakness of the preoperative portion of Neo-
ALTTO is that it lacked a blockade of the estrogen receptor
pathway, which is a well-described escape mechanism in HER2-
positive/HR-positive tumors (32,33). Our study corroborates these
laboratory findings and suggests that HER2 blockade in the ab-
sence of endocrine therapy has limited efficacy.
In future trials, we recommend the systematic stratification or
even separation of the 2 distinct biologic subsets, HER2-positive/
HR-negative and HER2-positive/HR-positive. For the latter pa-
tient group, a HER2 blockade combined with endocrine therapy
should be explored. This has already been done by Chang et al.,
who reported a pCR of 21% when using trastuzumab plus
lapatinib in combination with letrozole (34).
Our study was not powered to investigate the predictive value of
the early metabolic complete response that occurred in 21% (14/
66) of the patients at week 6, mostly patients with HR-negative
tumors. However, 10 of 14 of these early complete 18F-FDG PET/
CT responders showed pCR at surgery. Because pCR is a surrogate
of long-term outcome in this patient subset, independent valida-
tion of the apparently high correlation between an early metabolic
complete response in HER2-positive/HR-negative disease and pCR is
required. Early metabolic complete response could become an in-
novative way to separate patients well-served by existing anti-HER2
therapies from those who need additional or alternative ones.
Further work is required, however, and it includes determining
a better 18F-FDG PET/CT response threshold to distinguish re-
sponding from nonresponding patients. In our study, we opted to
use the EORTC threshold (15% at 2 wk), which is relatively low.
However, threshold choice should depend on a study’s particular
objective, with a high threshold most suited to identify the best
responders and a low threshold to identify nonresponders.
The strength of this imaging trial is the multicentric effort.
However, because of a lack of prior PET harmonization program,
absolute baseline values of SUVmax were not comparable among
cameras. Therefore, SUVs could not be pooled to study their
predictive value but only their relative changes.
CONCLUSION
Our study is the first, to our knowledge, to demonstrate that
early metabolic assessment using 18F-FDG PET/CT in patients
with HER2-positive BC is informative and can identify patients
with an increased likelihood of achieving pCR after anti-HER2
therapy combined with chemotherapy in the neoadjuvant setting.
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TABLE 3
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HR-negative HR-positive
Metabolic response pCR Non-pCR pCR rate pCR Non-pCR pCR rate
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